The minor variant of the single-nucleotide polymorphism rs3753381 affects the activity of a SLAMF1 enhancer

L. V. Putlyaeva, A. M. Schwartz, A. V. Klepikova, I. E. Vorontsov, I. V. Kulakovskiy, D. V. Kuprash

Research output: Contribution to journalArticlepeer-review


The SLAMF1 gene encodes CD150, a transmembrane glycoprotein expressed on the surface of T and B-lymphocytes, NK-cells, dendritic cells, and subpopulations of macrophages and basophils. We investigated the functional regulatory polymorphisms of the SLAMF1 locus associated with autoimmune processes, using bioinformatics and a mutational analysis of the regulatory elements overlapping with polymorphic positions. In the reporter gene assay in MP-1 and Raji B-cell lines, the enhancer activity of the regulatory region of the locus containing the rs3753381 polymorphism demonstrated a twofold increase upon the introduction of the rs3753381 minor variant (G → A) associated with myasthenia gravis. An analysis of the nucleotide context in the vicinity of rs3753381 revealed that the minor version of this polymorphism improves several binding sites for the transcription factors of FOX and NFAT, and RXR nuclear receptors. All mutations that disrupt any of these sites lead to a decrease in the enhancer activity both in MP-1 and in Raji cells, and each of the two B-cell lines expresses a specific set of these factors. Thus, the minor variant of the rs3753381 polymorphism may contribute to the development of myasthenia gravis by modulating SLAMF1 expression, presumably in pathogenic B-lymphocytes.

Original languageEnglish
Pages (from-to)94-102
Number of pages9
JournalActa Naturae
Issue number3
Publication statusPublished - 2017
Externally publishedYes


  • Autoimmunity
  • B cells
  • Noncoding polymorphism
  • Transcriptional regulation


Dive into the research topics of 'The minor variant of the single-nucleotide polymorphism rs3753381 affects the activity of a SLAMF1 enhancer'. Together they form a unique fingerprint.

Cite this